Table 1.
Completed studies of direct acting antivirals regimens in children and adolescents
|
Ref.
|
Year
|
Participant age in years (n)
|
HCV genotype
|
Therapy (duration)
|
SVR12 (%)
|
| Balistreri et al[50] | 2016 | 12-17 (100) | 1 | Ledipasvir 90 mg + sofosbuvir 400 mg (12 wk) | 98 |
| Wirth et al[51] | 2017 | 12-17 (52) | 2 or 3 | Sofosbuvir 400 mg + ribavirin (variable) | 98 |
| Hashmi et al[52] | 2017 | 5-18 (35) | 1 or 3 | Sofosbuvir 400 mg + ribavirin (variable) | 97 |
| El-Khayat et al[53] | 2018 | 12-17 (144) | 1, 4-6 | Ledipasvir 45 mg + sofosbuvir 200 mg (12 wk) | 99 |
| Murray et al[54] | 2018 | 6-11 (90) | 1 | Ledipasvir 45 mg + sofosbuvir 200 mg (12 wk) | 98 |
| El-Karaksy et al[55] | 2018 | 12-18 (40) | 4 | Ledipasvir 90 mg + sofosbuvir 400 mg (12 wk) | 100 |
| Leung et al[56] | 2018 | 12-17 (38) | 1 or 4 | Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin (variable) | 100 |
| Alkaaby et al[57] | 2018 | 7-18 (22) | Ledipasvir + sofosbuvir +/- ribavirin (variable) | 91 | |
| Tucci et al[58] | 2018 | 0.5 (1) | 4 | Ledipasvir 22.5 mg + sofosbuvir 100 mg (12 wk) | 100 |
| El-Shabrawi et al[59] | 2018 | 6-12 (20) | 4 | Ledipasvir 45 mg + sofosbuvir 200 mg (12 wk) | 95 |
| El-Shabrawi et al[60] | 2018 | 12-17 (10) | 1-6 | Sofosbuvir 400 mg + daclatasvir 60 mg (8 wk) | 100 |
| Yakoot et al[61] | 2018 | 12-17 (30) | 4 | Sofosbuvir + daclatasvir (12 wk) | 97 |
| Quintero et al[62] | 2019 | 6-18 (9) | 1 or 4 | Ledipasvir + sofosbuvir (variable) | 100 |
| Ghaffar et al[63] | 2019 | 8-18 (40) | 4 | Sofosbuvir + daclatasvir (variable) | 97.5 |
| Fouad et al[64] | 2019 | 11-17.5 (51) | 4 | Ledipasvir 90 mg + sofosbuvir 400 mg (12 wk) | 100 |
| Ohya et al[65] | 2019 | 10-13 (3) | 1b | Ombitasvir + paritaprevir + ritonavir (12 wk)Or glecaprevir + pibrenastavir (8 wk) | 100 |
| El-Shabrawi et al[66] | 2019 | 8-17 (20) | 4 | Sofosbuvir + Daclatasvir (12 wk) | 100 |
| Serranti et al[67] | 2019 | 12-17 (14) | 1 | Ledipasvir 90 mg + sofosbuvir 400 mg (8 wk) | 100 |
| Marascio et al[68] | 2019 | 13, 16 (2) | 4 | Ledipasvir 90 mg + sofosbuvir 400 mg (12 wk) | 100 |
| Fouad et al[69] | 2020 | 12-18 (46) | Not performed | Ledipasvir 180 mg + sofosbuvir 400 mg (12 wk) | 98 |
| Kamal et al[70] | 2020 | 3-6 (22) | 4 | Ledipasvir 45 mg + sofosbuvir 200 mg (8 or 12 wk) | 100 |
| El-Araby et al[71] | 2020 | 9-12 (100) | 4 | Ledipasvir 90 mg + sofosbuvir 400 mg (12 wk) | 100 |
| Rosenthal et al[72] | 2020 | 3-11 (54) | 1 or 4 | Sofosbuvir 400 mg + ribavirin (variable) | 98 |
| Schwarz et al[73] | 2020 | 3-< 6 (34) | 1 or 4 | Ledipasvir + sofosbuvir (variable) | 97 |
| Jonas et al74] | 2020 | 12-17 (47) | 1-4 | Glecaprevir 300 mg + pibrentasvir 120 mg (8-16 wk) | 100 |
| Wirth et al[75] | 2020 | 3-17 (57) | 1 or 4 | Elbasvir + grazoprevir (12 wk) | 100 |
| Sokal et al[76] | 2020 | 3-17 (216) | 1-4, 6 | Sofosbuvir + velpatasvir (12 wk) | 92 |
| Behairy et al[77] | 2020 | 4-10 (30) | 4 | Ledipasvir 45 mg + sofosbuvir 200 mg (8 wk) | 100 |
Table adapted from Squires et al[17]. HCV: Hepatitis C virus.